Companies /Healthcare

Scholar Rock Holding Corp

NASDAQ: SRRK Biotechnology
$48.00
▲ $2.92 (+6.48%) today
Markets closed · 4:39am ET

SRRK at a Glance

Valuation
Market cap
$5.5B
Profitability
Revenue (TTM)
$570,000
EPS (TTM)
$-3.23
Price
52-week range
$38 – $62
Street target
$70.06

Headquartered in Cambridge, MA Fiscal year ends December NASDAQ: SRRK scholarrock.com

About Scholar Rock

Scholar Rock Holding Corporation is a biopharmaceutical company focused on rare, severe neuromuscular diseases. Its work centers on myostatin biology, using a proprietary platform that develops monoclonal antibodies to selectively modulate protein growth factors.

Its lead product is ISEMBYLD (apitegromab-mstn), a muscle-targeted anti-myostatin antibody. The FDA approved it on September 11, 2026 for spinal muscular atrophy (SMA) in adults and children aged two and older who are already receiving an SMN2-targeted treatment. The approval was supported by the Phase 3 SAPPHIRE study. ISEMBYLD is now being commercialized in the U.S., with patient access supported through the Scholar Rock Supports hub.

The company is seeking approvals elsewhere:
- **European Union:** The MAA has been resubmitted, with a CHMP opinion expected in H1 2027.
- **Japan:** The JNDA is under priority review, with a launch anticipated near year-end 2027.
- **Global:** The company plans to expand access to up to 50 countries.

The pipeline includes:
- a subcutaneous apitegromab formulation
- the Phase 2 OPAL trial in SMA patients under age two
- the Phase 2 FORGE trial in facioscapulohumeral muscular dystrophy (FSHD)
- SRK-439, a next-generation subcutaneous myostatin inhibitor in Phase 1 Updated

Latest Activity

SRRKScholar Rock
Q3 2026
EPS
-$0.81
est -$0.84+4.0%
Revenue
$570K
est $284K+$286K

This is the first quarter Scholar Rock has ever booked product revenue, from initial ISEMBYLD stocking shipments after the September 11 FDA approval in SMA. More than a third of the top 140 U.S. treatment centers have already enrolled patients, though a drug-specific J-code does not arrive until April 2027.

Quarterly EPS — reported vs estimate

SRRK Coverage

1:55pm ET
Investing

Three Biotechs That Are Top Takeover Targets

Eli Lilly (NYSE:LLY | LLY Price Prediction) is the stock everyone wants to talk about, and the reasons are obvious: Mounjaro revenue jumped 125% to $8.66 billion last quarter, the company raised…

Alex Sirois

Frequently Asked Questions

What does Scholar Rock do?

Scholar Rock Holding Corporation is a biopharmaceutical company focused on rare, severe neuromuscular diseases. Its work centers on myostatin biology, using a proprietary platform that develops monoclonal antibodies to selectively modulate protein growth factors.

What is the SRRK stock price target?

The Wall Street consensus 12-month price target for SRRK is $70.06.